Straumann Holding AG (SAUHY)
12.78
+0.24
(+1.91%)
USD |
OTCM |
Dec 20, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 20.38B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -17.40% |
| Valuation | |
| PE Ratio | 68.18 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.182 |
| Price to Book Value | 9.307 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.0439 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 60.96% |
Profile
| Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The company’s core products are dental implants, and it holds roughly one third of the global implant dentistry market, which is estimated to be worth roughly CHF 5.4 billion. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands. |
| URL | https://www.straumann-group.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Feb. 27, 2025 (est.) |
| Last Earnings Release | Oct. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 25, 2024 |
Ratings
Profile
| Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The company’s core products are dental implants, and it holds roughly one third of the global implant dentistry market, which is estimated to be worth roughly CHF 5.4 billion. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands. |
| URL | https://www.straumann-group.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Feb. 27, 2025 (est.) |
| Last Earnings Release | Oct. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 25, 2024 |